SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

SANES

10.594

-1.38%↓

BBVA

19.585

-1.8%↓

BNP

93.25

-1.36%↓

CABK

11.515

-1.07%↓

INGA

26.335

-1.68%↓

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

176.7 -0.11

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

174.3

Max

177.1

Pagrindiniai rodikliai
By Trading Economics
Pajamos	41M 88M
Pardavimai	-11M 762M
P/E Sektoriaus vid.	62.036 58.051
Pelnas, tenkantis vienai akcijai	1.17
Pelno marža	11.569
Darbuotojai	10,456
EBITDA	26M 225M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+31.88% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.6B 17B
Ankstesnė atidarymo kaina	176.81
Ankstesnė uždarymo kaina	176.7

Naujienos nuotaikos

By Acuity

100%

410 / 439 reitingas Finance

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 20:30; UTC

Uždarbis

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026-06-02 23:58; UTC

Rinkos pokalbiai

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026-06-02 23:41; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026-06-02 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026-06-02 22:57; UTC

Rinkos pokalbiai

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026-06-02 22:50; UTC

Rinkos pokalbiai

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026-06-02 21:00; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-02 20:46; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:38; UTC

Uždarbis

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026-06-02 20:21; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:12; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Product Rev $594M

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Loss $177M >PANW

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

31.88% į viršų

12 mėnesių prognozė

Vidutinis 232.63 EUR 31.88%

Aukščiausias 262 EUR

Žemiausias 210 EUR

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

410 / 439 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.